Pulmonary Gas Exchange Response to Indacaterol in COPD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02547558|
Recruitment Status : Unknown
Verified September 2015 by Isabel Blanco, Hospital Clinic of Barcelona.
Recruitment status was: Not yet recruiting
First Posted : September 11, 2015
Last Update Posted : September 11, 2015
To evaluate the pulmonary gas exchange response to a therapeutic high dose of inhaled indacaterol (300 mcg) in 20 outpatients with stable symptomatic COPD B and D GOLD 2011 groups.
Measurements on a single day before and after 60 and 120 minutes of indacaterol will include arterial PO2, PaCO2 and pH. AaPO2; SaO2 (by pulse oximetry) and oxygen and carbon dioxide in exhaled breath, systemic arterial pressure and heart rate will also be measured/calculated. Cardiac output will be directly measured by bio-impedance.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Procedure: Arterial blood gases Procedure: Cardiac Output Procedure: Vital signs Procedure: Exhaled breath Procedure: Spirometry Drug: Indacaterol||Phase 4|
The investigators hypothesize that in stable chronic obstructive pulmonary disease (COPD) patients the interaction between intrapulmonary and extrapulmonary determinants contributing to gas exchange abnormalities after indacaterol will ultimately preserve arterial oxygenation (primary end-point outcome).
The study will include 20 outpatients with diagnosis of stable COPD in GOLD 2011 groups B and D (10 each), without frequent exacerbations (≥2 in the previous year). Patients with a COPD exacerbation within 3 months of study, use of long-term oxygen therapy and associated conditions or serious comorbidities (i.e., asthma, bronchiectasis, lung cancer and/or cardiovascular diseases) will be excluded.
Each patient will be studied on a single day. All subjects will remain on their regular treatment for the study. Subjects will be required to withhold SABAs for at least 12 h and LABAs and theophylline for at least 24 h before study. During measurements, patients will breath room air and will be seated in an armchair. Measurements will be performed before and 60 and 120 min after a single dose administration of indacaterol Breezhaler@ 300 mcg (1 inhalation).
After ensuring steady-state conditions, as assessed by stability (± 5%) of both ventilatory and hemodynamic variables, and by the close agreement (within ± 5%) between duplicate of mixed expired and arterial oxygen and carbon dioxide, a set of duplicate measurements for each variable will be obtained at each time point.
Blood samples will be collected through a catheter inserted under local anesthesia into the radial artery. Samples of blood (5 ml) will be removed for measurement of arterial O2 tension (PaO2), CO2 tension (PaCO2) and pH; alveolar-arterial PO2 difference (A-a)DO2, oxygen saturation (SaO2), and VO2, VCO2, Ve, respiratory rate (f), systemic arterial pressure (Psa), and heart rate (HR) will be measured or calculated, as previously described.
Cardiac output will be directly measured by bio-impedance. Spirometry values will be recorded from the history records of each patient. All measurements will be performed in the Centre de Diagnòstic Respiratori (CDR), Servei de Pneumologia, Institut del Tòrax, Hospital Clínic, Barcelona.
The primary outcome will be the PaO2 change after indacaterol at each analysis time. Based on a previous study in stable severe COPD patients using nebulized salbutamol during convalescence of exacerbation, Polverino et al. calculated that for a significant PaO2 fall of the order of 8 mmHg, a sample of 6 subjects is needed; this number was increased to 20 patients to ensure better data.
Secondary outcomes were changes in PaCO2, pH, the calculated D(A-a)DO2 and the response of cardiac output.
Results will be expressed as mean (±SEM) or median (95% CI). The effects of indacaterol on each of the end-point variables will be assessed by one-way repeated measures analysis of variance (ANOVA). Paired t tests and Pearson's correlation tests will be used as appropriate. All significances will be set at p<0.05, without correction for multiple tests.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients|
|Study Start Date :||October 2015|
|Estimated Primary Completion Date :||October 2015|
|Estimated Study Completion Date :||November 2015|
-Indacaterol, inhaled, single dose, 300 mcg
Procedure: Arterial blood gases
Measured through radial arterial catheter
Procedure: Cardiac Output
Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
Other Name: CO
Procedure: Vital signs
As measured in clinical practice
Procedure: Exhaled breath
Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
In a daily calibrated spirometer.
Indacaterol Breezhaler@ 300 mcg (1 inhalation)
Other Name: Ultra long acting beta 2 agonist
- Change in PaO2 after indacaterol. [ Time Frame: 60 and 120 minutes ]
- Change in PaCO2 after indacaterol. [ Time Frame: 60 and 120 minutes ]
- Change in D(A-a)DO2 after indacaterol. [ Time Frame: 60 and 120 minutes ]
- Change in pH after indacaterol. [ Time Frame: 60 and 120 minutes ]
- Change in cardiac output after indacaterol. [ Time Frame: 60 and 120 minutes ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02547558
|Contact: Isabel Blanco, MD, PhD||+34 649539835||IBLANCO2@clinic.ub.es|
|Hospital Clínic||Not yet recruiting|
|Barcelona, Spain, 08036|
|Contact: Isabel Blanco, MD, PhD +34 649539835 firstname.lastname@example.org|
|Principal Investigator:||Isabel Blanco, MD, PhD||Hospital Clínic|